Because retinol does not by itself activate the nuclear receptors for retinoic acid: the cell must first oxidise it to retinaldehyde and then to retinoic acid, and only that final molecule binds the RAR receptors. That double conversion explains both retinol's lower potency and its better tolerance.
Published 7 September 2026. Last reviewed 9 September 2026.
Definitions used in this article
- Retinoid. Any compound derived from vitamin A, natural or synthetic, with the ring and polyene chain structure characteristic of that family.
- Retinol. The alcohol form of vitamin A. Formula C20H30O, molecular weight 286.5 g/mol, CAS 68-26-8.
- Retinaldehyde. The aldehyde form, intermediate between retinol and retinoic acid. Formula C20H28O, molecular weight 284.4 g/mol, CAS 116-31-4.
- Retinoic acid (tretinoin). The acid form, and the only one of the three that binds the nuclear receptors directly. Formula C20H28O2, molecular weight 300.4 g/mol, CAS 302-79-4. It is a prescription drug substance, not a cosmetic ingredient.
- RAR and RXR. Two families of nuclear receptors which, bound to one another as a heterodimer, regulate the transcription of retinoid-dependent genes.
- Retinyl ester. The storage form of retinol inside the cell, obtained by esterification with a fatty acid.
The metabolic route, step by step
Conversion occurs through two successive oxidations. Szymański and colleagues describe it in Cells (2020): retinol is oxidised by retinol dehydrogenases to become retinaldehyde, with subsequent oxidation by the retinaldehyde dehydrogenases RALDH1, RALDH2 and RALDH3 to retinoic acid.
The two steps are not equivalent. The first is reversible: the enzyme DHRS3 can return retinaldehyde to retinol. The second is not - the conversion of retinaldehyde to retinoic acid is irreversible - so the cell regulates retinoic acid production principally by controlling the reversible step that precedes it.
Once formed, retinoic acid binds the RAR receptor, which undergoes a structural change leading to dissociation of the corepressor complex, and acts bound to RXR, since RXRs are the obligatory heterodimerisation partners of RARs and of several other nuclear receptors. Without that binding there is no transcriptional signal. This is why the conversion is not a pharmacokinetic detail but the requirement for activity.
What the conversion costs: the quantitative evidence
The reference work is that of Kurlandsky, Xiao, Duell, Voorhees and Fisher, published in The Journal of Biological Chemistry in 1994. In human keratinocytes the authors observed that retinol is converted predominantly into retinyl esters and produces retinoic acid in low, dose-dependent amounts. Retinol reduced the activity of a cutaneous enzyme and activated reporter genes at concentrations approximately ten times higher than those required with retinoic acid. Decisively for interpretation, blocking the conversion substantially inhibited those responses: the responses induced by retinol are mediated by its tightly regulated conversion to retinoic acid.
Three consequences follow, and they are worth stating plainly. The first is that a percentage of retinol on a label is not comparable with the same percentage of retinoic acid: in the system studied the difference was an order of magnitude. The second is that most of the retinol entering the cell is not converted but stored as an ester. The third is that enzymatic capacity is finite, so the relationship between applied concentration and retinoic acid generated cannot be assumed linear indefinitely.
Comparison of the three forms
| Property | Retinol | Retinaldehyde | Retinoic acid |
|---|---|---|---|
| Molecular formula | C20H30O | C20H28O | C20H28O2 |
| Molecular weight (g/mol) | 286.5 | 284.4 | 300.4 |
| CAS number | 68-26-8 | 116-31-4 | 302-79-4 |
| Oxidation steps to retinoic acid | Two | One | None |
| Binds RAR directly | No | No | Yes |
| Irritation in the first four weeks (Fluhr et al., 1999) | Low irritant potential, equivalent to that of retinaldehyde (p < 0.05 vs. retinoic acid) | Erythema, scaling and stinging significantly less frequent than with retinoic acid (p < 0.0001) | Erythema in 44%, scaling in 35%, stinging in 29% of participants |
| Status in the EU | Restricted cosmetic ingredient (Annex III, Regulation (EU) 2024/996) | Cosmetic ingredient; not included in that restriction | Prescription drug substance; not permitted as a cosmetic ingredient |
Tolerance: the order the literature describes
Fluhr and colleagues compared the three molecules in Dermatology (1999) through patch testing over fourteen days and clinical follow-up across forty-four weeks. Under maximised conditions they found an equally low irritation potential for retinol and retinaldehyde and a more pronounced irritant effect with retinoic acid (p < 0.05). Over the long term, retinoic acid produced erythema, scaling and stinging in 44%, 35% and 29% of participants respectively during the first four weeks, and all three parameters were significantly less frequent with retinaldehyde (p < 0.0001).
The result is coherent with the mechanism: the molecule that reaches the receptor directly, without passing through enzymatic control, is also the one that produces more local reaction. Retinol's lower irritancy is not an independent property that can be claimed as a standalone advantage; it is the other face of its lower potency.
The European framework, since 1 November 2025
Commission Regulation (EU) 2024/996 of 3 April 2024 introduced retinol, retinyl acetate and retinyl palmitate into Annex III of Regulation (EC) No 1223/2009, with maximum concentration limits in the product ready for use:
- 0.05% retinol equivalent (RE) in body lotion.
- 0.3% RE in all other products, both leave-on and rinse-off.
The timetable is twofold. From 1 November 2025, cosmetic products containing those substances that do not meet the conditions may not be placed on the Union market; from 1 May 2027 they may not be made available either. The regulation adds a labelling obligation: products containing retinol, retinyl acetate or retinyl palmitate must carry the statement Contains Vitamin A. Consider your daily intake before use, in the language required by the member state of sale.
Two points are frequently lost when this change is reported. The first is that the limit is expressed in retinol equivalents, not as a percentage of the raw material: an ester contributes to the total only the fraction corresponding to its retinol content, not its whole weight. The second is that retinaldehyde does not appear in this Annex III entry and is therefore not subject to these limits; it does not follow that it is equivalent in activity, nor that it escapes the safety-assessment obligations Regulation (EC) No 1223/2009 imposes on every cosmetic ingredient.
For readers in the United States the relevant contrast is structural rather than numerical. All-trans retinoic acid is a drug substance available only on prescription, while retinol is used as a cosmetic ingredient; United States cosmetic regulation sets no concentration ceiling for retinol equivalent to the Annex III entry described above. A formulation compliant in one market is therefore not automatically compliant in the other, and the difference is regulatory, not biochemical: the conversion route described in this article is the same on both sides of the Atlantic.
What questions this evidence allows
The metabolic chain described turns several habitual assertions into verifiable questions. If a product declares a retinol concentration, is it expressed in retinol equivalents, and does it meet the Annex III limit applicable to its category where that applies? If it is compared with retinoic acid, does the comparison acknowledge the roughly order-of-magnitude potency difference documented in human keratinocytes? If tolerance is presented as an advantage, is it presented alongside the potency figure that accompanies it? None of these questions is answered by the words advanced, clinical or medical-grade.
Scope note
This article describes findings published in the peer-reviewed literature, certified physical properties of isolated compounds, and the text in force of European cosmetic products legislation. It does not constitute a claim about the properties, efficacy or effects of any product, and nothing in it should be read as asserting that a cosmetic product prevents, treats or cures any disease or physiological alteration. Retinoic acid is mentioned in its capacity as the active substance of prescription medicines; its description here is bibliographic and implies neither availability nor recommendation of use. This text does not replace the advice of a healthcare professional.
References
- Kurlandsky, S.B., Xiao, J.H., Duell, E.A., Voorhees, J.J. and Fisher, G.J. (1994). Biological activity of all-trans retinol requires metabolic conversion to all-trans retinoic acid and is mediated through activation of nuclear retinoid receptors in human keratinocytes. The Journal of Biological Chemistry 269(52), 32821-32827. DOI 10.1016/s0021-9258(20)30065-x. PMID 7806506.
- Szymański, Ł., Skopek, R., Palusińska, M., Schenk, T., Stengel, S., Lewicki, S., Kraj, L., Kamiński, P. and Zelent, A. (2020). Retinoic Acid and Its Derivatives in Skin. Cells 9(12), 2660. DOI 10.3390/cells9122660.
- Fluhr, J.W., Vienne, M.P., Lauze, C., Dupuy, P., Gehring, W. and Gloor, M. (1999). Tolerance profile of retinol, retinaldehyde and retinoic acid under maximized and long-term clinical conditions. Dermatology 199(Suppl. 1), 57-60. DOI 10.1159/000051381. PMID 10473963.
- Commission Regulation (EU) 2024/996 of 3 April 2024 amending Annexes II, III, V and VI to Regulation (EC) No 1223/2009. EUR-Lex, CELEX 32024R0996.
- Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. EUR-Lex, CELEX 32009R1223.
- Molecular weights, formulas and CAS numbers: certified product data from Cayman Chemical for vitamin A / all-trans retinol (item 20241), all-trans retinal (18449) and all-trans retinoic acid (11017).
Published by the Research Team, https://www.ttsclinical.com/